603014.SHG Shandong Weigao Blood
- Market cap
- CNY 23.7B
- P/E
- 21.2x
- P/B
- 2.16x
- ROE
- 6.4%
- Dividend yield
- 0.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 603014.SHG undervalued?
Graham number603014.SHG trades 42.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Weigao Blood fundamental analysis
No fundamental analysis for Shandong Weigao Blood yet.
Shandong Weigao Blood stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Weigao Blood
Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China. It offers dialyzers; dialysis machines; hemodialysis tubing, products, and machines; peritoneal dialysis products; dialysis supporting products, such as hemoperfusion devices, dialysis powder and liquid, puncture needles, and iodine caps for peritoneal dialysis. It also offers prefillable syringe drug delivery sy…
Full company profileShandong Weigao Blood financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Weigao Blood annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 2.91B | 3.43B | 3.53B | 3.60B | 3.77B | 3.52B |
| Gross Profit | 1.35B | 1.47B | 1.54B | 1.52B | 1.52B | 1.33B |
| Operating Income | 351M | 387M | 1.54B | 557M | 557M | 528M |
| EBITDA | - | 660M | 690M | 788M | 825M | 529M |
| Net Income | 260M | 315M | 442M | 449M | 482M | 460M |
| EPS | 0.74 | 0.85 | 1.19 | 1.21 | 1.15 | 1.10 |
| Balance Sheet | ||||||
| Total Assets | 5.94B | 6.41B | 6.68B | 6.99B | 8.61B | 8.47B |
| Total Liabilities | 2.26B | 1.74B | 1.55B | 1.39B | 1.49B | 1.24B |
| Shareholders' Equity | 3.68B | 4.67B | 5.14B | 5.60B | 7.12B | 7.23B |
| Cash & Short-term Investments | 330M | 589M | 646M | 818M | 1.58B | 1.24B |
| Cash Flow | ||||||
| Operating Cash Flow | 505M | 727M | 288M | 572M | 794M | - |
| Capital Expenditure | 401M | 280M | 233M | 179M | 160M | 97.7M |
| Free Cash Flow | 104M | 448M | 288M | 393M | 634M | 160M |
| Ratios | ||||||
| ROE | 7.1% | 6.7% | 8.6% | 8.0% | 6.8% | 6.4% |
| ROA | 4.4% | 4.9% | 6.6% | 6.4% | 5.6% | 5.4% |
| Net Profit Margin | 8.9% | 9.2% | 12.5% | 12.5% | 12.8% | 13.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shandong Weigao Blood dividends
- Dividend yield
- 0.28%
- Forward dividend
- 0.57 CNY
- Payout ratio
- 13.6%
- Ex-dividend date
- Sep 14, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 65.8M | 0.16 | 13.6% |
| 2024 | - | - | - |
| 2023 | CNY 488K | 0.00 | 0.1% |
| 2022 | CNY 18.8M | 0.05 | 6.0% |
| 2021 | CNY 42.7M | 0.12 | 16.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Shandong Weigao Blood
- Insiders 89.08%
- Institutions 2.85%
- Public & others 8.06%
- Shares outstanding 695M
- Free float 196M
Shandong Weigao Blood company profile
- Company name
- Shandong Weigao Blood
- Ticker
- 603014.SHG
- ISIN
- CNE100007093
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 3,734
- Fiscal year end
- December
- Address
- No. 7, Weigao West Road, Weihai, China, 264200
- Phone
- 86 63 1571 6143
- Website
- wego-healthcare.com
About Shandong Weigao Blood
Shandong Weigao Blood Purification Products Co., Ltd. engages in the research and development, production, and sale of blood purification medical products in China. It offers dialyzers; dialysis machines; hemodialysis tubing, products, and machines; peritoneal dialysis products; dialysis supporting products, such as hemoperfusion devices, dialysis powder and liquid, puncture needles, and iodine caps for peritoneal dialysis. It also offers prefillable syringe drug delivery systems. The company was founded in 2004 and is based in Weihai, China.
Shandong Weigao Blood management
6- Mr. Cunming ZhangGM & Director · born 1976
- Mr. Jingang ZhangCFO & Accounting Supervisor · born 1973
- Ms. Xiaoyun ChenDeputy GM & Director · born 1974
- Mr. Changjun MouDeputy GM & Director · born 1982
- Ms. Tingting WangBoard Secretary · born 1987
- Mr. Ji WangDeputy General Manager · born 1972